Literature DB >> 27349913

Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.

Moo-Kon Song1, Joo-Seop Chung2, Sung-Nam Lim3, Gyeong-Won Lee4, Sang-Min Lee5, Nam-Kyung Lee6, Jae-Cheol Choi7, So-Yeon Oh8.   

Abstract

Although splenomegaly is major characteristic of primary myelofibrosis (PMF), splenomegaly has been devalued due to a less reliable method based on physical examination (PEx). We evaluated whether spleen volume (SV) on CT would accurately predict clinical outcomes in PMF. A total of 188 patients were enrolled. SV was quantitated by the automatic volume software. In ROC curve, the SV predicted prognosis more accurately than spleen length by PEx (p < 0.001). The ideal cut-off value was 378.1 cm(3) for SV, which was divided into high- and low-volume status. Patients with low SV status had superior leukemia-free survival and overall survival compared to high SV status (p < 0.001, p < 0.001) In the Cox analysis, old age ≥65 years (p = 0.004, p = 0.001), low Hemoglobin <10.0 g/dL (p = 0.023, p = 0.021), high WBC counts ≥25 × 10(9)/L (p = 0.003, p = 0.006), peripheral blasts ≥1 % (p = 0.029, p = 0.020), unfavorable cytogenetic abnormalities (p = 0.025, p = 0.028), and high SV status (p = 0.004, p = 0.003) were independently associated with survivals. SV measured by CT was important for predicting survival in patients with PMF.

Entities:  

Keywords:  Computed tomography; Overall survival; Primary myelofibrosis; Splenic volume; Splenomegaly

Mesh:

Year:  2016        PMID: 27349913     DOI: 10.1007/s12185-016-2050-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  29 in total

1.  Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.

Authors:  Katerina E Panteli; Eleftheria C Hatzimichael; Paraskevi K Bouranta; Afroditi Katsaraki; Konstantinos Seferiadis; Justin Stebbing; Konstantinos L Bourantas
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

2.  Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases.

Authors:  J T Reilly; J A Snowden; R L Spearing; P M Fitzgerald; N Jones; A Watmore; A Potter
Journal:  Br J Haematol       Date:  1997-07       Impact factor: 6.998

3.  Anaemia in myelofibrosis: its value in prognosis.

Authors:  O S Njoku; S M Lewis; D Catovsky; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

4.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

5.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

Authors:  B Dupriez; P Morel; J L Demory; J L Lai; M Simon; I Plantier; F Bauters
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

6.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

7.  International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

Authors:  Kebede Hussein; Animesh D Pardanani; Daniel L Van Dyke; Curtis A Hanson; Ayalew Tefferi
Journal:  Blood       Date:  2009-11-09       Impact factor: 22.113

8.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

9.  Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.

Authors:  Cody A Koch; Chin-Yang Li; Ruben A Mesa; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2003-10       Impact factor: 7.616

10.  The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis.

Authors:  J B Miller; J R Testa; V Lindgren; J D Rowley
Journal:  Cancer       Date:  1985-02-01       Impact factor: 6.860

View more
  4 in total

Review 1.  Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.

Authors:  Moo-Kon Song; Byeong-Bae Park; Ji-Eun Uhm
Journal:  Int J Mol Sci       Date:  2018-03-18       Impact factor: 5.923

2.  Association between cellular immune response and spleen weight in mice with hepatocellular carcinoma.

Authors:  Wei Jiang; Yu Li; Shuqun Zhang; Guangyao Kong; Zongfang Li
Journal:  Oncol Lett       Date:  2021-06-30       Impact factor: 2.967

3.  Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Authors:  Maria-Theresa Krauth; Sonja Burgstaller; Veronika Buxhofer-Ausch; Günther Gastl; Klaus Geissler; Felix Keil; Peter Krippl; Thomas Melchardt; Andreas Petzer; Holger Rumpold; Thamer Sliwa; Stefan Wöhrer; Albert Wölfler; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2018-07-24       Impact factor: 1.704

4.  Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).

Authors:  Razan Hayati Zulkeflee; Zefarina Zulkafli; Muhammad Farid Johan; Azlan Husin; Md Asiful Islam; Rosline Hassan
Journal:  Int J Environ Res Public Health       Date:  2021-07-16       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.